APLS — Apellis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.25bn
- $5.30bn
- $1.00bn
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Citi, Truist trim PT on Biogen ahead of Q1 earnings
Deals of the day-Mergers and acquisitions
Street View: Biogen's $5.6 billion Apellis bet a strategic fit
Deals of the day-Mergers and acquisitions
U.S. RESEARCH ROUNDUP- Asana, PPG Industries, Verisign
Press Digest: Wall Street Journal - April 1
Deals of the day-Mergers and acquisitions
Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio (updated)
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
Brief: Biogen To Buy Apellis For $5.6 Billion To Boost Kidney Franchise - Bloomberg News
Apellis Q4 product revenue driven by SYFOVRE sales
Brief: Apellis Pharmaceuticals Q4 Basic EPS USD 0.47
Brief: Apellis Announces Eight Oral Presentations At The 49Th Macula Society Annual Meeting
U.S. RESEARCH ROUNDUP- Amazon, Apple, Cigna
Apellis Q3 revenue jumps to $459 mln with Sobi payment
U.S. RESEARCH ROUNDUP-Mongdob, Quaker Houghton, Regeneron Pharmaceuticals
Apellis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Apellis Pharmaceuticals Q2 Basic EPS USD -0.33